Scotiabank keeps USD 558.00 target for Vertex Pharma stock

Published on 10/27/2026 at 17:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 3.33 billion in second-quarter 2026, up 12.50 percent. Vertex Pharma stock costs EUR 462.45 on October 27, 2026, up 0.85 percent.

Scotiabank target dated October 26, 2026

Scotiabank maintained a Buy rating and a USD 558.00 target on October 26, 2026.
Second-quarter revenue reached USD 3.33 billion, up 12.50 percent year over year.
Vertex Pharma stock costs EUR 462.45 at Lang & Schwarz on October 27, 2026 at 5:46 p.m. CET, 0.85 percent above the Tradegate close.
Vertex will report third-quarter results on November 2, 2026.

Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

Scotiabank maintained its Buy rating on Vertex Pharma and set a USD 558.00 price target on October 26, 2026, according to Markets Insider. That target is 8.25 percent above the Nasdaq price of USD 515.47. At Lang & Schwarz, Vertex Pharma was trading at EUR 462.45 on October 27, 2026 at 5:46 p.m. CET, up 0.85 percent versus the Tradegate close of October 26, 2026 at EUR 458.55.

Revenue remains the key support

Vertex reported USD 3.33 billion in revenue for the second quarter of 2026, up 12.50 percent from USD 2.96 billion a year earlier. Net income reached USD 1.10 billion, compared with USD 1.03 billion in the second quarter of 2025, according to Markets Insider. The revenue increase gives the upcoming results release a clear numerical benchmark.

Nasdaq price and valuation

On Nasdaq, Vertex last traded at USD 515.47 on October 27, 2026 at 12:48 p.m. EDT. Its 52-week range was USD 403.16 to USD 560.25, placing the price 7.99 percent below the high and 27.79 percent above the low. The market capitalization was USD 130.7 billion and the price-to-earnings ratio was 29.98 on the same date.

What dates matter next?

Vertex will report third-quarter 2026 results after the market closes on November 2, 2026, with a conference call scheduled for 4:30 p.m. ET, according to Vertex Pharmaceuticals. A separate regulatory milestone for povetacicept is scheduled for November 30, 2026, the PDUFA target action date reported by FinanzNachrichten.

Comparison with peers

Vertex Pharma: up 0.85 percent, P/E 29.98, market capitalization USD 130.7 billion.

Bristol-Myers Squibb (NYSE, USD): down 0.54 percent, P/E 13.49, market capitalization USD 125.2 billion.

Gilead Sciences (Nasdaq, USD): down 0.34 percent, negative P/E, market capitalization USD 196.1 billion.

Stock stays below its yearly high

The euro quotation is 0.85 percent above the Tradegate close, while the Nasdaq price remains 7.99 percent below its 52-week high. The combination leaves the November 2 reporting date as the next concrete test for the valuation.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.